Zanubrutinib

Class
Targeted therapy
Subclass
Bruton tyrosine kinase inhibitors
Substance name
Zanubrutinib
Brand names
Brukinsa®
Common formulations
Gelatin-coated capsule
Dosage and administration
Adults patients
Chronic lymphocytic leukemia
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Follicular lymphomaRelapsed or refractory, received ≥ 2 prior lines of systemic therapy
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Administered in combination with obinutuzumab.
Mantle cell lymphomaReceived at least one prior therapy
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Marginal zone lymphomaRelapsed or refractory, received at least one anti-CD20-based regimen
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Small lymphocytic lymphoma
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Waldenstrom's macroglobulinemia
320 mg PO daily, in 1-2 divided doses, until disease progression or unacceptable toxicity
Indications for use
Labeled indications
Adults
Treatment of Waldenstrom's macroglobulinemia
Treatment of chronic lymphocytic leukemia
Treatment of follicular lymphoma (relapsed or refractory, received ≥ 2 prior lines of systemic therapy)
Treatment of mantle cell lymphoma (received at least one prior therapy)
Treatment of marginal zone lymphoma (relapsed or refractory, received at least one anti-CD20-based regimen)
Treatment of small lymphocytic lymphoma
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource